Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer

Revenues disappoint, but new products rise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer

1Q Revenues: $13.5 billion (-9%)
 
1Q Earnings: $2.8 billion (+53%)
 
Comments: Primary Care sales were down 21% to $3.2 billion impacted a 55% drop in Lipitor revenues and loss of exclusivity and near-term expiration of co-promotion agreements for Aricept and Spiriva. These declines were partially offset by Lyrica sales, up 12% to $1.1 billion. Oncology sales were up 31% to $372 million, driven by recent launches Inlyta and Xalkori in several major markets. Specialty Care sales were down 11% to $3.2 billion. Buying patterns for Prevnar 13 hurt revenues. Emerging Markets sales were up 6% to $2.4 billion. Established Product sales were down 15% to $2.4 billion. Consumer Healthcare sales were up 12% to $811 million. R&D Expenses were $1.7 billion, down 3%. Earnings reflect divested interest in Zoetis.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters